Work

The Combination of Pegylated Liposomal Doxorubicin and Bortezomib Significantly Improves Time to Progression of Patients with Relapsed/Refractory Multiple Myeloma Compared with Bortezomib Alone: Results from a Planned Interim Analysis of a Randomized Phase III Study.

Year: 2006

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v108.11.404.404

Authors: Robert Z. Orlowski, Sen H. Zhuang, Trilok Parekh, Liang Xiu, Jean-Luc Harousseau, the DOXIL-MMY-3001 Study Investigators

Institutions: University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, Janssen Research & Development (United States), Centre Hospitalier Universitaire de Nantes

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2994184201

FWCI: 3.988

Cites:

Cited by: 25

Related to: 10